Skip to main content
. Author manuscript; available in PMC: 2020 Oct 24.
Published in final edited form as: Clin Infect Dis. 2020 Oct 23;71(7):1704–1714. doi: 10.1093/cid/ciz1034

Figure 2.

Figure 2.

Comparisons of postvaccination geometric mean antibody titers in each of the enhanced vaccine groups, compared to the postvaccination geometric mean titer in the standard-dose QIV group (n = 200 individuals per group). Values significantly different from 1.0 are highlighted in bold. Note that a B/Yamagata lineage virus was not included in the MF59-adjuvanted TIV and the high-dose TIV. Antigens used were A/Singapore/GP1908/2015 (A/Michigan/45/2015[H1N1]-like virus); A/Hong Kong/4801/2014(H3N2), with both egg-propagated and cell-propagated variants; B/Brisbane/60/2008; and B/Phuket/3073/2013. Abbreviations: CI, confidence interval; GMT, geometric mean titer; GMTR, geometric mean titer ratio comparing post-vaccination geometric mean titers between enhanced vaccine groups and the standard dose group; HA, hemagglutinin; HAI, hemagglutination inhibition assay; MN, microneutralization assay; QIV, quadrivalent influenza vaccine; TIV, trivalent influenza vaccine.